News
News

Owkin and Cleveland Clinic develop an artificial intelligence model that predicts liver cancer prognosis

5 min read

22-09-2021, New York and Cleveland

Owkin, a startup that deploys artificial intelligence (AI) and Federated Learning technologies to augment medical research and enable scientific discoveries, presented findings in Hepatocellular Carcinoma (HCC) with Cleveland Clinic at the 2021 European Society of Medical Oncology (ESMO) conference. The collaborative research leverages Cleveland Clinic’s high-quality datasets and world-class medical research and Owkin’s pioneering technologies and research platform.

Cleveland Clinic researchers, led by Federico Aucejo, MD, Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic, have collaborated with Owkin to develop and validate a deep learning model that predicts survival and outcome of HCC patients following liver transplantation. This was performed on 298 whole-slide images stained with haematoxylin/eosin and clinical data from HCC patients who had a liver transplant at Cleveland Clinic. 

The findings showed the deep learning model trained on histopathology data predicted recurrence among transplant patients both in the whole cohort and in subgroups of patients treated with or without loco-regional therapy prior to transplantation. These results were comparable to a separate model that incorporated clinical, biological, and pathological data. Most significantly, combinations of both histological and clinical models outperformed scoring systems currently used in the literature. Taken together, this study demonstrates the prognostic power of deep learning applied to histology slides to predict the recurrence of HCC patients following liver transplantation.

“Machine learning technology is emerging to revolutionize the world we live in. Its application in patient populations, risk stratification and personalized medicine is expected to enhance safety and allow for a more cost-effective healthcare environment. In line with this, partnerships and alliances among healthcare networks and the tech industry will be instrumental to paving the way towards this paradigm change,” Dr. Aucejo said. “This collaboration resulted in the development of an algorithm to predict outcome in patients undergoing liver transplantation with HCC by scrutinizing histopathology digital slides. This approach proved to be superior to predict tumour recurrence than conventional metrics.”

“Our collaborative research aims to advance the prediction of HCC patient outcomes and identify prognostic markers following treatment. The richness and uniqueness of Cleveland Clinic’s research cohorts, together with Owkin’s extensive expertise in developing predictive AI models, can pave the way for a breakthrough, forward-thinking science and will allow the opportunity to further develop our collaboration in future research areas,” Meriem Sefta, PhD, Chief Data and Clinical Solutions said.

HCC is amongst the leading causes of cancer-related deaths in the world, representing ~90% of primary liver cancers. Currently, liver transplantation remains the best treatment for cirrhotic patients with early-stage HCC, however, tumour recurrence following liver transplant is observed in 15-20% of cases, which correlates with poor survivorship. Moreover, there are currently no reliable histological markers of relapse-free survival in HCC patients following a liver transplant, which is critical in predicting patient prognosis.

Building on these results, additional deep-learning models and multimodal models developed on medical imaging, molecular, and genomics data, in addition to clinical and histopathological data, will shed further insights into diagnostic and biomarkers that may predict HCC prognosis and survivorship following treatment to improve patient care and long-term outcomes.

About Owkin

Owkin is a French-American startup that specializes in AI and Federated Learning for medical research. Owkin’s mission is to connect the global healthcare industry through the safe and responsible use of data and the application of artificial intelligence, for faster and more effective research. Owkin was founded in 2016 by Dr Thomas Clozel M.D., a clinical research doctor and former assistant professor in clinical haematology, and Dr Gilles Wainrib, Ph.D., a pioneer in the field of artificial intelligence in biology

Owkin leverages life science and machine learning expertise to make drug development and clinical trial design more targeted and cost-effective. Owkin applies its cutting-edge machine learning algorithms across a broad network of academic medical centres, creating dynamic models that not only predict disease evolution and treatment outcomes, but can also be used in clinical trials for enhanced analysis, high-value subgroup identification, development of novel biomarkers, and the creation of both synthetic control arms and surrogate endpoints. The end goal is to discover better treatments for patients, developed faster, and at a lower cost.

Owkin has published several high-profile scientific achievements in top journals such as Nature MedicineNature CommunicationsHepatology and presented results at conferences such as the American Society of Clinical Oncology.

For more information, please visit www.owkin.com, follow @OWKINscience on Twitter

Media contact:  Talia Lliteras at talia.lliteras@owkin.com